Skip to content

Study · Non-randomized trial · 2014

3 results

[Using deltalicin for the treatment of patients with diabetic retinopathy].

Kresiun NV, Godlevskiĭ LS

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2014

PMID25739189 (opens in a new tab)PepBankPUB-25739189
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with diabetic retinopathy, two months of intranasal deltalicin (delta sleep-inducing peptide) decreased the latent period of the visual evoked potential.

    In plain wordsIn people with diabetic retinopathy, intranasal delta sleep-inducing peptide shortened the delay of the eye's electrical response.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseVEP latent period
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye
    Studied dose
    0.0003 g daily · intranasal · two monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months) decreased the latent period and led to less pronounced depression of VEP amplitude in patients with diabetic retinopathy, and reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s.
    1 context sentence
    Summary · context
    The characteristics of visual evoked potential (VEP) have been investigated in a group of 15 healthy volunteers (aged 31.7 ± 3.6 years) and 30 insulin-dependent patients (aged 32.1 ± 4.0 years) with diabetes mellitus, among which 15 patients suffered from diabetic retinopathy and 15 patients had no retinopathy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with diabetic retinopathy, deltalicin led to less pronounced depression of VEP amplitude after photostress.

    In plain wordsIn people with diabetic retinopathy, the peptide treatment left the eye's electrical response less weakened after bright light.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseVEP amplitude depression after photostress
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye
    Studied dose
    0.0003 g daily · intranasal · two monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months) decreased the latent period and led to less pronounced depression of VEP amplitude in patients with diabetic retinopathy, and reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s.
    1 context sentence
    Summary · context
    The characteristics of visual evoked potential (VEP) have been investigated in a group of 15 healthy volunteers (aged 31.7 ± 3.6 years) and 30 insulin-dependent patients (aged 32.1 ± 4.0 years) with diabetes mellitus, among which 15 patients suffered from diabetic retinopathy and 15 patients had no retinopathy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with diabetic retinopathy, deltalicin reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s.

    In plain wordsIn people with diabetic retinopathy, the peptide treatment shortened the time for the eye's electrical response to recover after bright light.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseRestoration time of VEP characteristics after photostress
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye
    Studied dose
    0.0003 g daily · intranasal · two monthsAs given in this study (human).

    Measurements

    VEP restoration time
    95.1 s
    deltalicin-treated diabetic retinopathy

    Source sentences

    Summary
    Treatment with deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months) decreased the latent period and led to less pronounced depression of VEP amplitude in patients with diabetic retinopathy, and reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s.
    2 context sentences
    Summary · context
    The restoration of VEP characteristics in 73.5 ± 3.3 s from the moment of photostress was observed in the control group, while this index in both subgroups of diabetic patients without and with retinopathy was 88.7 ± 5.9 and 137.2 ± 11.3 s, respectively.
    Summary · context
    The characteristics of visual evoked potential (VEP) have been investigated in a group of 15 healthy volunteers (aged 31.7 ± 3.6 years) and 30 insulin-dependent patients (aged 32.1 ± 4.0 years) with diabetes mellitus, among which 15 patients suffered from diabetic retinopathy and 15 patients had no retinopathy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.